| 4.21 0.1 (2.43%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.35 | 1-year : | 5.88 |
| Resists | First : | 4.58 | Second : | 5.03 |
| Pivot price | 4.06  |
|||
| Supports | First : | 3.83 | Second : | 3.19 |
| MAs | MA(5) : | 4.13 |
MA(20) : | 4.1 |
| MA(100) : | 3.82 |
MA(250) : | 4.07 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.8 |
D(3) : | 23.8 |
| RSI | RSI(14): 51.6 |
|||
| 52-week | High : | 7 | Low : | 2.66 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ATHE ] has closed below upper band by 16.6%. Bollinger Bands are 43.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.4 - 4.42 | 4.42 - 4.45 |
| Low: | 4.09 - 4.11 | 4.11 - 4.13 |
| Close: | 4.18 - 4.21 | 4.21 - 4.24 |
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Fri, 12 Jun 2026
50-for-1 reverse split reshapes Alterity (NASDAQ: ATHE) capital base - Stock Titan
Tue, 09 Jun 2026
Alterity Therapeutics (ATHE) Gets FDA Nod for Phase 3 Program - GuruFocus
Tue, 09 Jun 2026
Alterity secures FDA alignment on pivotal Phase 3 trial for MSA drug - grafa.com
Tue, 09 Jun 2026
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder - Benzinga
Tue, 09 Jun 2026
Alterity Therapeutics (ATHE) Secures FDA Agreement for Phase 3 A - GuruFocus
Tue, 09 Jun 2026
Alterity, FDA agree on phase 3 program for multiple system atrophy asset ATH434 - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 18 (M) |
| Shares Float | 8,320 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 8 (K) |
| Shares Short P.Month | 20 (K) |
| EPS | -0.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.14 |
| Profit Margin | -219.9 % |
| Operating Margin | -372.6 % |
| Return on Assets (ttm) | -32.6 % |
| Return on Equity (ttm) | -47.1 % |
| Qtrly Rev. Growth | 74.5 % |
| Gross Profit (p.s.) | 0.35 |
| Sales Per Share | 0.36 |
| EBITDA (p.s.) | -0.97 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -8.1 |
| PEG Ratio | 0 |
| Price to Book value | 1.96 |
| Price to Sales | 11.49 |
| Price to Cash Flow | -5.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|